文献速递神经肿瘤

靶向下一代测序 panel(TruSight Tumor 170)在弥漫性胶质瘤中的应用:单中心135例经验

Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
PubMed 文献 · J Neurooncol · 2019-02-01

该研究纳入135例按WHO标准诊断的弥漫性胶质瘤样本,评估TruSight Tumor 170 panel的DNA与RNA测序表现。DNA分析检出常规技术所识别的全部突变且与各亚型已知突变高度一致,RNA分析检出4个融合基因及1个剪接变异。作者认为该panel有望提高诊断准确性与预后判断,IDH野生型弥漫性胶质瘤可能获益最大。

要点

  • TruSight Tumor 170 panel的DNA分析可检出常规技术所识别的全部突变,与各亚型已知突变高度一致。
  • RNA分析检出PTPRZ1-MET、FGFR3-TACC3、FAM131B-BRAF、RET-CCDC6融合及EGFR vIII剪接变异。
  • 1p/19q共缺失的少突胶质瘤中检出1p和19q位点基因的聚集性拷贝数丢失。

核心结论

  • 在临床和实验室环境中应用基于TruSight Tumor 170 panel的下一代测序有望提高诊断准确性和预后判断。
  • 作者认为IDH野生型弥漫性胶质瘤可能获益最大,该组为遗传异质性肿瘤,携带大量癌基因和抑癌基因的DNA序列改变、拷贝数变异和融合。

研究设计与样本

  • 单中心机构经验,分析135例按WHO标准基于组织学特征和常规分子检测(包括免疫染色、1p/19q FISH以及MGMT甲基化和TERT启动子突变分析)诊断的弥漫性胶质瘤样本。

主要发现

  • 135例包括38例IDH突变型[17例星形细胞瘤、13例少突胶质瘤和8例胶质母细胞瘤]、87例IDH野生型(6例星形细胞瘤、3例少突胶质瘤和78例胶质母细胞瘤)和10例弥漫性中线胶质瘤H3K27M突变型。
  • DNA分析检出这些样本中常规技术所识别的全部突变,结果与各亚型已知突变高度一致。
  • RNA分析检出4个融合基因,包括PTPRZ1-MET、FGFR3-TACC3、FAM131B-BRAF和RET-CCDC6,以及1个剪接变异(EGFR vIII突变)。
  • 在1p/19q共缺失的少突胶质瘤中检出1p和19q位点基因的聚集性拷贝数丢失。

临床怎么用

  • 作者认为在临床和实验室环境中应用基于TruSight Tumor 170 panel的下一代测序有望提高诊断准确性和预后判断。
  • 作者认为IDH野生型弥漫性胶质瘤可能获益最大。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. METHODS: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation. RESULTS: A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. DNA analysis enabled the detection of all mutations identified in these samples by conventional techniques, and the results were highly comparable to the known mutations in each subtype. RNA analysis detected four fusion genes including PTPRZ1-MET, FGFR3-TACC3, FAM131B-BRAF, and RET-CCDC6 and one splicing variant (EGFR vIII mutant). Clustered copy number loss in 1p and 19q loci genes were detected in 1p/19q-codeleted OD. CONCLUSIONS: The application of TST-170 panel based NGS in clinical and laboratory setting is expected to improve diagnostic accuracy and prognostication. Most benefits are expected in IDH-wildtype DG, a group of genetically heterogenous tumors harboring DNA sequence changes, copy number alterations, and fusions in a large number of oncogenes and tumor suppressor genes.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Na K, Kim HS, Shim HS, et al. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. J Neurooncol. 2019. PMID: 30710203. doi:10.1007/s11060-019-03114-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。